No one should have to fear blindness from glaucoma.

– Thomas M. Brunner, President and CEO

“We accelerate new and safe solutions for glaucoma patients.”

– Andrew G. Iwach, MD, Chair, Board of Directors

2016 ANNUAL REPORT

our FOCUS

finding a cure.

“If you’ve got glaucoma, GRF is the best community out there—they’re looking forward for the cure.”

– Catherine Wilmoth and her son, Christopher who was diagnosed with glaucoma when he was 7 months old.

We are a catalyst for game-changing diagnostics, for innovative treatment options, and ultimately for a cure. This bold vision requires intense focus, careful planning, thoughtful and creative research funding, and meaningful education and outreach. Thank you for your ongoing partnership. Together, we are closer than ever to achieving Vision for Life for all who have glaucoma and are at risk of glaucoma.

Andrew G. Iwach, MD
President and CEO

Thomas M. Brunner
Chair, Board of Directors

VISION

for life.
Dear Friends,

At Glaucoma Research Foundation, our bold vision is a future without glaucoma. With generous support from you and others dedicated to our mission we can make Vision for Life a reality for all those at risk and suffering from glaucoma. We are a catalyst for game-changing diagnostics, for innovative treatment options, and ultimately for a cure. This bold vision requires intense focus, careful planning, thoughtful and creative research funding, and meaningful education and outreach. Thank you for your ongoing partnership. Together, we are closer than ever to achieving Vision for Life for all who have glaucoma and are at risk of glaucoma.

Andrew G. Iwach, MD
Chair, Board of Directors

Thomas M. Brunner
President and CEO

Thomas N. Brunner
President and CEO
Andrew G. Iwach, MD
Chair, Board of Directors
David T. Stark, MD, PhD
David Geffen School of Medicine, University of California, Los Angeles, California

Grants for Innovative Glaucoma Research, gifts from The Frank Stein and Paul S. May Foundation, were made possible through leadership built on the knowledge and discoveries of many great predecessors. We know that research is the answer—research holds the answers…and the cure.

Some of the most important discoveries in scientific research come from an investigator with a new, untested idea who needs funding to explore a creative project.

Visit glaucoma.org/grants to learn more about our 2016 research grants.
Grants for Innovative Glaucoma Research, gifts from The Frank Stein and Paul S. May grants were made possible through leadership scientists and laboratories. The 2016 research built on the knowledge and discoveries of many. We know that research is the answer—research holds the answers…and research grants were funded at $40,000 each to explore promising new ideas.

Some of the most important discoveries in scientific research come from an investigator with a new, untested idea who needs funding to explore a creative project.
• Founded 1978 in San Francisco
• Speeding the cure through research collaboration
• Raising awareness and educating the public
• Leading the way in glaucoma research until a cure is found

Prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.

SCIENTIFIC ADVISORS

Balwantray Chauhan, PhD
Dalhousie University, Nova Scotia

George A. Cioffi, MD
Columbia University College of Physicians and Surgeons

Anne L. Coleman, MD, PhD
Stein Eye Institute, UCLA

Scott Fraser, PhD
University of Southern California

Christopher A. Girkin, MD
University of Alabama at Birmingham

David S. Greenfield, MD
University of Miami

Steven L. Mansberger, MD, MPH
Devers Eye Institute/Legacy Health

Martin Raff, MD
University College, London

Douglas Rhee, MD
Case Western Reserve University School of Medicine

Joel S. Schuman, MD
New York University School of Medicine

Ernst R. Tamm, MD
University of Regensburg, Germany

Monica Vetter, PhD
University of Utah

Martin B. Wax, MD
PanOptica, Inc.

Arthur J. Weber, PhD
Michigan State University

Janey L. Wiggs, MD, PhD
Massachusetts Eye & Ear Infirmary
The Catalyst for a Cure research team brings together four laboratories, each with a specific skill, to work together to discover new biomarkers. Sensitive biomarkers will help doctors diagnose glaucoma earlier and treat it more effectively. In 2016 the team has made significant progress toward biomarker validation for clinical use.

“We borrow ideas from astronomy, microscopy, mathematics, even chemistry and apply them to the study of glaucoma.”

Alfredo Dubra, PhD
Associate Professor of Ophthalmology and Biophysics
Department of Ophthalmology, The Eye Institute
Medical College of Wisconsin

“We are deeply committed to making a difference in the lives of glaucoma patients.”

Andrew Huberman, PhD
Associate Professor, Departments of Neurobiology and Ophthalmology
Stanford University School of Medicine

“The Biomarker Initiative catalyzes our ability to move candidate therapies from the laboratory to the clinic.”

Jeffrey L. Goldberg, MD, PhD
Professor and Chair of Ophthalmology
The Byers Eye Institute at Stanford

“Biomarkers can detect the progression of glaucoma at a stage where it can be prevented.”

Vivek Srinivasan, PhD
Assistant Professor of Biomedical Engineering
University of California, Davis
Department of Biomedical Engineering
What are Biomarkers? And Why are they So Important?

Early detection. Early diagnosis is the key to preventing vision loss. Sensitive biomarkers hold the potential to let doctors detect the disease early, before sight is permanently lost.

Faster drug discovery. Glaucoma progresses slowly. An effective biomarker could demonstrate the efficacy of a drug more quickly and accelerate federal approval for new treatments.

More effective treatment. Biomarkers could help doctors learn sooner if a treatment is working or not, helping them to treat glaucoma patients more effectively.

Closer to a cure. The more we understand about biomarkers the closer we are to discovering the root causes of the disease—and the cure.

Learn more at glaucoma.org/catalyst
Total revenue for the fiscal year ended June 30, 2016 was $3.8 million. Through generous support from our donors, $3.5 million was committed to essential glaucoma research and education programs. Glaucoma Research Foundation continues to have a strong balance sheet, finishing the year with total assets of $9.7 million.

Independent nonprofit evaluators Charity Navigator and GuideStar give us high ratings for transparency and accountability. Our audited financial reports are available on our website and we meet all 20 of the Better Business Bureau’s Standards for Charity Accountability. Careful stewardship ensures that 86 cents of every dollar donated goes directly to research and education programs.

This year we have committed one million dollars to the collaborative Catalyst for a Cure Biomarker Initiative. This type of major commitment requires steadfast support. We need your help to close a funding gap and meet our ambitious goals in the coming fiscal year.

Thank you for your personally significant contributions and your ongoing advocacy to help speed the cure.

Charles Wilmoth
Treasurer
## Glaucoma Research Foundation

### Statement of Activities for the Year Ended June 30, 2016*

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unrestricted</td>
<td>Temporarily Restricted</td>
</tr>
<tr>
<td><strong>SUPPORT AND REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations and bequests</td>
<td>$2,166,042</td>
<td>$955,297</td>
</tr>
<tr>
<td>Special Events, net of expenses</td>
<td>418,260</td>
<td>-</td>
</tr>
<tr>
<td>Other Income/Reductions</td>
<td>3,861</td>
<td>-</td>
</tr>
<tr>
<td>Investment Income</td>
<td>(10,438)</td>
<td>(69,599)</td>
</tr>
<tr>
<td>Change in value of charitable trusts</td>
<td>(3,162)</td>
<td>-</td>
</tr>
<tr>
<td>Conference/Forum income</td>
<td>363,400</td>
<td>-</td>
</tr>
<tr>
<td>Assets released from restrictions</td>
<td>430,269</td>
<td>(430,269)</td>
</tr>
<tr>
<td><strong>Total Revenue, gains, &amp; support</strong></td>
<td><strong>3,368,232</strong></td>
<td><strong>455,429</strong></td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Programs</td>
<td>2,544,735</td>
<td>-</td>
</tr>
<tr>
<td>Education Programs</td>
<td>919,803</td>
<td>-</td>
</tr>
<tr>
<td>Administration</td>
<td>129,534</td>
<td>-</td>
</tr>
<tr>
<td>Fundraising</td>
<td>426,857</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>4,020,929</td>
<td>4,020,929</td>
</tr>
<tr>
<td><strong>Change in Net Assets</strong></td>
<td>(652,697)</td>
<td>455,429</td>
</tr>
<tr>
<td><strong>Net Assets, beginning of year</strong></td>
<td>3,235,752</td>
<td>1,850,108</td>
</tr>
<tr>
<td><strong>Net Assets, end of year</strong></td>
<td><strong>$2,583,055</strong></td>
<td><strong>$2,305,537</strong></td>
</tr>
</tbody>
</table>

### Statement of Financial Position as of June 30, 2016*

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$1,249,612</td>
<td>$666,585</td>
</tr>
<tr>
<td>Pledges and bequests receivable</td>
<td>390,278</td>
<td>186,610</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>111,952</td>
<td>118,567</td>
</tr>
<tr>
<td>Booklet inventory</td>
<td>35,330</td>
<td>31,822</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td><strong>1,787,172</strong></td>
<td><strong>1,003,584</strong></td>
</tr>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pledges and bequests receivable</td>
<td>592,523</td>
<td>108,000</td>
</tr>
<tr>
<td>(net of present value discount and current portion)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assets held in trust (at market value)</td>
<td>188,742</td>
<td>191,947</td>
</tr>
<tr>
<td>Investments (at market value)</td>
<td>3,743,727</td>
<td>4,959,650</td>
</tr>
<tr>
<td>Furniture and equipment (net of depreciation)</td>
<td>28,476</td>
<td>33,096</td>
</tr>
<tr>
<td>Permanently restricted cash</td>
<td>3,342,500</td>
<td>3,342,500</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT ASSETS</strong></td>
<td><strong>7,895,968</strong></td>
<td><strong>8,635,193</strong></td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$9,683,140</strong></td>
<td><strong>$9,638,777</strong></td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>134,434</td>
<td>50,261</td>
</tr>
<tr>
<td>Trusts, distributions payable, current portion</td>
<td>22,131</td>
<td>25,907</td>
</tr>
<tr>
<td>Grants payable</td>
<td>1,192,500</td>
<td>1,035,000</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td><strong>1,349,065</strong></td>
<td><strong>1,111,168</strong></td>
</tr>
<tr>
<td><strong>NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities to trust beneficiaries (at present value)</td>
<td>102,953</td>
<td>99,219</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td><strong>1,452,018</strong></td>
<td><strong>1,210,387</strong></td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>2,583,085</td>
<td>3,235,782</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>2,305,537</td>
<td>1,850,108</td>
</tr>
<tr>
<td>Permanently restricted net assets</td>
<td>3,342,500</td>
<td>3,342,500</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td><strong>8,231,122</strong></td>
<td><strong>8,428,390</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td><strong>$9,683,140</strong></td>
<td><strong>$9,638,777</strong></td>
</tr>
</tbody>
</table>

*Audited Financial Report
In Appreciation

We express our deepest appreciation to all of our donors. Each and every gift is essential and assists us with forwarding our important mission.

The following is a listing of contributors of $500 or more from July 1, 2015 to June 30, 2016.

CORPORATIONS AND FOUNDATIONS

Benefactors ($100,000 to $199,999)
The Alcon Foundation, Inc.

Pacesetters ($25,000 to $49,999)
Alcon Laboratories, Inc.
The Allergan Foundation Allergan, Inc.
Bausch + Lomb
Edward Joseph Daly Foundation
Medical Research Charities
MUFG Union Bank N.A.
Ora, Inc.

Patrons ($10,000 to $24,999)
Aerie Pharmaceuticals, Inc.
Akorn, Inc.
Canon USA, Inc.
Carl Zeiss Meditec, Inc.
Carol Young Brooke Foundation
Dodge & Cox
Elite Island Resorts
Genentech, Inc.

Patrons ($10,000 to $24,999)
Aerie Pharmaceuticals, Inc.
Akorn, Inc.
Canon USA, Inc.
Carl Zeiss Meditec, Inc.
Carol Young Brooke Foundation
Dodge & Cox
Elite Island Resorts
Genentech, Inc.

Sponsors ($5,000 to $9,999)
Allstate Life Insurance Company
Delta Gamma Foundation Diopsys, Inc.

Contributors ($500 to $999)
Chevron Humankind Employee Funds

Concrete Technology Corporation
Disneyland Resort
GE Foundation
Haag-Streit USA, Inc.
Hinomaru Limousine Co., Ltd.
Hyatt Lodge at McDonald’s Campus
Kaur Photography
Larabar
Lynnwood Retired Eagles Activity Club
Marines’ Memorial Association
Michael Merrill Design Center
Microsoft Matching Gifts Program
Oakley, Inc.
Presidio Golf Club
PRP Wine International
Shopify
The Boeing Company Gift Matching Program
thrive SF Fitness
Wines for Humanity

INDIVIDUALS

Benefactors ($200,000+)
Rubin - Obstgarten - Cohn Family
Mona and Edward Zander

Benefactors ($100,000 to $199,999)
Charlot and Dennis E. Singleton
Liz Stratton

Founders ($50,000 to $99,999)
Mr. and Mrs. F.T. Barr
Olcott Family Foundation

Founders ($50,000 to $99,999)
Mr. and Mrs. F.T. Barr
Olcott Family Foundation

Founders ($50,000 to $99,999)
Mr. and Mrs. F.T. Barr
Olcott Family Foundation

Pacesetters ($25,000 to $49,999)
Wallace and Thomas M. Brunner
Margaret and Russell Garvin
Carie and Larry Haimovitch
Steven and Michele Kirsch

Patrons ($10,000 to $24,999)
Michael and Darlene Arnold
Sarah and Bill Brown
Jill and Michael Chmura
Germaine and Timothy Dwyer, Wendy Dwyer Memorial
Mrs. Frances Vaughan Hunt
Andrew G. Iwach, MD
Roberta R.W. Kameda
The Link Family
James and Rebecca Morgan
Janet and Cary Rayment
Margaret Reynolds
Robert H. and Cary L. Cohn Family Foundation
Virginia M. Shaffer
Emmett Skinner, Jr.
Frank Stein
Anupama and Matthew Tate
Catherine and Charles Wilmoth

Sponsors ($5,000 to $9,999)
Chris W. Allen, DVM
Arlene Anthony and Thomas Bradshaw
Frederick H. and Cynthia L. Brinkmann
Paul and Paula Chaney
Barry Friedberg
Frank and Joseph Gila Fund
Adrienne L. Graves, PhD
David S. Kline
Charles and Jane Kusek
Patricia Lee
Lawrence S. Lipkind, DDS
Kathryn Mayer
Dhun Mehta

In our BOLD VISION the cure is in sight.
Continued from page 10.

Judith and Charles Munnerlyn, PhD
Angela Nomellini and Kenneth E. Olivier
David T. Richardson, West Charitable Trust
Stephanie Twomey Roche and N. D’Arcy Roche
Randolph C. Roeder
John Russell
Naomi and Robert Stamper, MD
Lisa and Martin B. Wax, MD
Todd Zander
Thelma H. Zeller

Catalyst Circle
($1,000 to $4,999)

Allen S. Taylor Foundation
Thea Amberg
Fred Amoroso
Mr. Roger Anderson
Weston and Jeannette Anderson
Betty J. Annis
Anonymous
K. Arakelian Foundation
Thomas Baker
Michael S. Barish
Daniel Barry
Lezlie Beam
Hugh Beckman, MD
Tatyana Beldock
Arleen and Robert Belyea
Susan Benton
Michael Bergamini, PhD
Robert F. Blitzer and Xerney
Richard Bondurant
Robert F. Blitzer and Xerney
Michael Bergamini, PhD

Amanda Eddy
William Edlund
Carolyn B. Edward
Michael and Tracey Elfstrom
Emily Farina
Robert D. Fechtner, MD
Marilyn A. Fenneman and Alex Forrester
Donald Fishbein
Anthony R. Fisher, PhD
Scott J. Fudemberg, MD
Martin and Gwen Gans
Gilbert H. Gates
Marlene Gerbsman
LaRue R. Gibson, Jr.
Judy F. Gordon, DVM
Nancy M. Graydon
Gary Greenberg
Richard C. Greenwald
Cathy and Rod Gremaud
Sharlene and Alfred Hall, PharmD
Carol M. Hall
Louise and Rick Halprin, CPA
Tracy Hammond
Marjorie D. Hart
Yehia Hashad, MD
Paul Heiman
John Hetherington, Jr., MD
Ann and H. Dunbar Hoskins, Jr., MD
Takashi Izuka
Manraj Johl
The Kahn Foundation
Robert Karp
Jerrold Keilson
Jean D. Kliewer
Martin Knight
Bradye Krone
Andrew J. Kujawa
Mark R. and Rae N. Lembersky
Norma S. Lenhert
Alvin and Rosanne Levitt
Richard A. Lewis, MD
Grace Lin
Linda and Donald Linck, DDS
Margaret London
Jane R. Lurie
Mrs. Donna F. Mahin
Grace and George R. Marcellino, PhD
Isao S. Matsuura
Liam Mayclem
Julia J. McMahon
Andrew C. Meyer, Jr.
Michael and Ina Korek Foundation Trust
Elizabeth B. and Carl V. Migliazzio, MD
Chris and Anny Monteilh

James R. Morano, PhD
Robert and Maura Morey
Christopher M. Morgan
Lawrence and Liz Morris
Seymour and Pearl Moskowitz
Geeta Narendra Ahya
Carolyn M. Neerhof
Debbie and Robert C. Nevins
Marjorie A. Nevitt
Howard Noddell
Vincent E. O’Brien
Masashi Oka
Judy F. Oliphant
Charlotte L. Petty
Denise and Sam Polakoff
Robert L. Pondelieck
Deirdre Porter and Bradford Hall
Hardy and Ellie Prentice
David E. I. Pyott
P. Anthony Ridder
Carol and George Rogers
Patricia A. Rospenda
Donald Schwartz, MD
Karen Schwartz and Sam Shelanski
Alan and Ellyn Seelenfreund
Patrick J. Shuler
Saul Siemaska
Mary R. Skuce
Terry and Peggy Slattery
Laine and Carl Smith
Stephen E. Smith
Jeffrey and Nancy Soluri
Michael Speyer
Richard Steegstra
Tania W. Stepanian
Bill and Jane Stocklin
Lynn Streim
Joyce Suchsland
Shigemi Sugiki, MD, FACS
Arthur S. Takahara
Catherine and Richard Tate
Harry T. Tate, MD
Marian and Julius Tills Endowment Fund of the Dallas Jewish Community Foundation
Dr. and Mrs. Thomas G. Todaro
Carolyn and Matthew Vanderberg
Monica Vetter, PhD
Rebecca and Steven Vilendrer
Barbara and Robert Voss
Vincent A. Wallace
Angela Webb, Moon Joggers
Wendy Weisler

Dr. and Mrs. George M. Weston, In Loving Memory of Daniel S. Weston
Sally O. White
John and Cynthia Wied
Candace Williams
Ruth D. Williams, MD and Stephen C. Gieser, MD, MPH
Leslie and Mike Winn
Harvey and Susan Wittenberg
Katherine A. Wood
Bruce and Katrina Woodske
Ratna K. Yadla, MD
Cheryl and Thomas Young
Jackie and Phillip Young

Contributors
($500 to $999)

Robert Adams
Rory Anderson
Stephen Andolina
Paul Ashton, PhD
Jack and Carol Aten
Arthur Back
Murat Baday
David Bailey
Mary and Timothy Barnes
J. Bronwyn Bateman, MD and Douglas Hershey, MD
Micah Bates
Nancy and Joseph Blum
Jeffrey Boyum
Breitman Family Foundation, Inc.
Chris Brown
William F. Cael
Joan Carroll
Jermaine Christie
William and Michele Ciganek
Jeff Cleland
Rob Cook
Craig Corbitt and Nancy Stolitz
Thomas Cordero
Emmett Cunningham, Jr., MD, PhD, MPH
Ken J. Damozzoni
Edward Danse
Dick Davis
Maryam Mehri Dehnavi
Diana Leis Delker
Venkat and Prema Devarajan
Jeffrey J. Drzazgowski
Kim Ennis
Sharon Farahani
Sina Fateh
Steven and Debra Fendrich
Jeff Finer, MD
Dan Finkle
Continued from page 11.

Douglas C. Fisher, MD
Elizabeth Flagg
Cynthia Foster
Doug Foster
Dr. Larry Freeman
Bradley Fundingsland
Ken Galt
Mike Garanzini
Zoya Gargiulo
Craig German
Avanti Ghanekar
Susan Glikbarg Hanson
Phillip Gooding
Margaret and Joseph F. Govednik
Lisa Grillone
Mr. and Mrs. Harold E. Guenther
Kinta Haller
Martha Hamilton
Robert T. Harker
Karen Harris
Paul Harvey, Jr.
Peggy Hawkins
Theresa Heah
Patrick Healy, MPH
Harold U. Hernandez
Lilo Hoffman
Les and Eleanor Holve
Lori and Mark Horne
Kamran Hosseini
Vera Hsu
Dr. Charles A.C. Johnson
Dan Joraanstad and
Bob Hermann
Jim Kasic
Tooran Khayambashi
Hugh Kirkpatrick
Daniel Kohane
Bill and Carolyn Kolzow
Susan Kramer
Dr. Jens Kratholm
Achim H. Krauss
Grace David Land
Diane Lee
Elizabeth A. Lee and
Marty Oster
Ken Leong
Robert Levine, MD
Howard and Susan Licht
Randy Lindholm
Laura and Steven M.
Litinsky, MD
Dr. Fenghe Lu
Andrew Luk
Robert and Delores Lyons
Kelley MacDonald and R.
Thomas Martell, Jr.
Leah Makley
Linda Marcinek
Morton Marott
Rev. and Mrs. Alexander
McLachlan
Stanley Michael
Dorothy M. Miles
Joan and Wayne Miller
Sandra Moss
David and Jane Newsom
Weston Nichols
Thomas J. Nico
George N. Nikopoulos
Anthony and Linda Nolan
T. Michael Nork, MD
Donna and Gary D. Novack,
PhD
Vandy O’Reilly
John and Alice Osterman
Anton Petrov
Nancy and Charles Philipp
Christine Phipps
Stephanie Pilgrim
Michael Piser
Alan and Carol Pomerantz
Gene M. Pranzo
Rory Priday
Mary Jane Rafii, MBA, PhD
Federico Rampini
Gale Richards
Michael Robinson, MD
Andrew Rockefeller
Michael Rowe
Cheryl Rowe-Rendleman,
PhD
Anne L. Brody Rubin
Roman Rubio, MD
Susan Ryu, MD and
Michael Gaynond, MD
Misako M. Sack
Ronald Sanders
Robert and Rosemary
Schaffer
Sheila Schlee
Charles L. Schmidt
Susan Schneider
Todd Scott
Erik Scramaglia
Craig T. Woodbury
Andrew Sedgwick
Charles Semba, MD
Timothy Seno
Grace Seto
Naj Sharif, PhD
Ken Shimokawa
Edwin Shonfeld, MD
Erwin Si, PhD
Nicholas Siemasko
Nelson Singleton
Robert Spratlin
Vivek Srinivasan, PhD
Douglas Steward
Martha C. Stisser
Eric Strauss
Craig Sundstrom
Emiko Sung
William Swart
John D. Swayne
James Tan, MD, PhD
Sarah Tao
Kevin Tausend
Kathy M. Thomas
Vincent Tuccillo
Tracy Valerie, BS, MBA
David Van Meter
Margrit Vanderryn
Hazel H. Wada
Gary Walker, PhD
Margo Walker
Brian A. Welcome, MD
Jane Weston, MD and Jan
Horn, MD
Barbara Wirostko, MD
Sue and Richard Wollack
Peter Woo
Yi Yin
M.P. and B. J. Zimprich

ADDITIONAL
CONTRIBUTORS
We are grateful to the
more than 3,200 donors
who have contributed in
fiscal year 2016 to forward
our mission. Thank you for
your steadfast support.

THE
BLANCHE
MATTHIAS
SOCIETY
The Blanche Matthias Society recognizes
those individuals who have included Glaucoma
Research Foundation in their estate plans.
We are grateful to the following individuals
who have notified us of their intent to include us
as a beneficiary in their wills, trusts, or other
investment vehicles.

Steven Aberblatt
MariLynn Bagienski
Schuyler and Susie Bailey
Andrew Balaban
Diana Belliveau
Gerald Beresniewicz
Barbara J. Bethune
Frances O. Blair
Wallace and Thomas M.
Brunner
Barbara R. Conway
Donald J. Digby, MD, FACS,
FAAO
Robert J. Drabkin
Sharon Entwistle
Arla Escontrias
Charleen Evans-Thomas,
EdD
John Filozof
Marina L. Flores
Carol Gasiorek
E. Y. and William O. Geisert
Gloria Greenlee
Larry Haimovitch
Ron Strickland and
Christine Hartmann
Ruth M. Henning
Andrew G. Iwach, MD
Virginia Johansen-Hudnall
Esther Jones
Shirley Kalgaard
Arlyne Krum
Nancy Lam
Laurence Lande
Sharon Leahy
Donald Loesch
Charles K. Long
Jane R. Lurie
Richard Malm
Dolores Nieves
Nunes Living Trust
Marnay O’Neal
Charlotte L. Petty
Patricia A. Pomerleau
Betty Riess
Barbara J. Ritzenthaler
Cheryle Rost
Mary J. Schaal
Judith Schnorf
Marianne Seidenberger
Emmett Skinner, Jr.
Sara Marie Smith
Mary Ann Spicer
Burton Spiller
William Steckowich
Frank Stein
Brian P. Vaughan
Carol E. Vistnes
Michael T. Walczyk
Mel Walker
Craig T. Woodbury
And three anonymous
members

For more information
on the Blanche Matthias
Society, visit our website at
glaucoma.org/involved or
contact us at 415-986-3162.
This honor roll is composed
of major donors who
supported Glaucoma
Research Foundation from
July 1, 2015 to June 30,
2016. If your name has
been omitted or there is an
error in the listing, we ask
that you notify us at
251 Post Street, Suite 600,
San Francisco, CA 94108
or call 415-986-3162.
We know that research is the answer—research built on the knowledge and discoveries of many scientists and laboratories. The 2016 research grants were made possible through leadership gifts from The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research, and Dr. James and Elizabeth Wise. These one-year research grants were funded at $40,000 each to explore promising new ideas.

Some of the most important discoveries in scientific research come from an investigator with a new, untested idea who needs funding to explore a creative project.
No one should have to fear blindness from glaucoma.

– Thomas M. Brunner, President and CEO

We accelerate new and safe solutions for glaucoma patients.

– Andrew G. Iwach, MD, Chair, Board of Directors

251 Post Street, Suite 600, San Francisco, CA 94108 – (415) 968-3162 – www.glaucoma.org

GRF Council

A national leadership council of physicians working with GRF to improve access to informative and unbiased educational materials for all glaucoma patients.

Chair, GRF Council
Carl Migliazzo, MD
(Central Regional Councilor)

GRF Councilors

Sharr F. Ball, MD
Robert J. Barnes, MD
Michael S. Berlin, MD
Kathryn Bollinger, MD
Steven V. Broyen, MD, FACS
Dean Carlton, MD
John S. Cohen, MD
(Redwood Regional Councilor)
Randy Crawn, MD
Robert J. Derick, MD
Monta Dinks, MD
Amih Doshi, MD
Ezraeen Fazio, MD
Robert Feldman, MD
(Southwest Regional Councilor)
Gloria P. Fleming, MD
David Gilbert, MD
Linda Greff, MD
Agnes Huang, MD
Dan, Jewellwitz, MD
Martin B. Kaback, MD
L. Jay Katz, MD
(Northeast Regional Councilor)
Anup Khatana, MD
Douglas Koli, MD
Michael S. Korney, MD
Rishi Krishna, MD
Rishi Kumar, MD

Linda Lawrence, MD
Richard Lehrer, MD
Steve Littmany, MD
(Southwest Regional Councilor)
Charles McMahon, MD
(Mountain Regional Councilor)
Anne Miller, MD
Kevin Miller, MD
Johanne Ohly, MD
David J. Palmer, MD
Cindy Pendlser, MD
James Piotrowski, MD, FACS
Andrew Princis, MD
Andrew Rabinowitz, MD
George Reiss, MD
Michael Sakamoto, MD
(Western Regional Councilor)
Keith Sanford, MD
Sonia W. Schuller, MD, MPH
Bradley Schuster, MD
(Mountain Regional Councilor)
Arthur L. Schwartz, MD
Donald Schwartz, MD
Gail F. Schwartz, MD
My La Shaw, MD
Rajesh Shetty, MD
Charles Eric Shreader, MD
Okeueastos Smi, MD
(Southwest Regional Councilor)
Michael Stiles, MD
Yogeswari Supp, MD
Thomas Taylor, MD
Steven Vold, MD
(Southern Regional Councilor)
Brian Welcome, MD
Mark Werner, MD
Ruth D. Williams, MD
(Midwest Regional Councilor)
Jeffrey Zink, MD

If you’ve got glaucoma, GRF is the best community out there—they’re looking forward for the cure.

– Catherine Wilmoth and her son, Christopher who was diagnosed with glaucoma when he was 7 months old.

We accelerate new and safe solutions for glaucoma patients.

– Andrew G. Iwach, MD, Chair, Board of Directors

“Vision for Life”

Dear Friends,

At Glaucoma Research Foundation, our bold vision is a future without glaucoma. With generous support from you and others dedicated to our mission we can make Vision for Life a reality for all those at risk and suffering from glaucoma. We are a catalyst for game-changing diagnostics, for innovative treatment options, and ultimately for a cure. This bold vision requires intense focus, careful planning, thoughtful and creative research funding, and meaningful education and outreach. Thank you for your ongoing partnership. Together, we are closer than ever to achieving Vision for Life for all who have glaucoma and are at risk of glaucoma.

Andrew G. Iwach, MD
President and CEO

Thomas M. Brunner
Chair, Board of Directors

VISION for life.